Allogene Therapeutics, Inc. (ALLO)
USD 1.91
(-7.97%)
USD 1.91
(-7.97%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -237.73 Million | -220.51 Million | -184.81 Million | -115.09 Million | -137.35 Million | -44.65 Million |
| Net Income | -327.26 Million | -332.63 Million | -257 Million | -250.22 Million | -184.59 Million | -211.5 Million |
| Depreciation & Amortization | 14.19 Million | 14.29 Million | 10.45 Million | 7.58 Million | 5.02 Million | 1.5 Million |
| Deferred income taxes | 7.5 Million | 8.07 Million | 10.39 Million | 4.4 Million | -331 Thousand | -117 Thousand |
| Stock-based compensation | 65.95 Million | 83.6 Million | 80.81 Million | 65.26 Million | 46.06 Million | 18.56 Million |
| Change in working capital | -15.3 Million | 3.7 Million | -32.08 Million | 53.92 Million | -6.87 Million | 12.09 Million |
| Other non-cash items | 17.18 Million | 2.43 Million | 2.61 Million | 3.95 Million | 3.36 Million | 134.8 Million |
| Investing Cash Flow | 163.28 Million | 106.15 Million | 163.65 Million | -505.12 Million | 164.08 Million | -632.79 Million |
| Investments in PPE | -1.51 Million | -5.19 Million | -21.44 Million | -65.95 Million | -50.79 Million | -3.23 Million |
| Acquisitions | -164.8 Million | -111.35 Million | -17.71 Million | 439.16 Million | -5.07 Million | - |
| Investment purchases | -438.62 Million | -248.1 Million | -525.58 Million | -1.03 Billion | -252.62 Million | -649.3 Million |
| Sales/Maturities of investments | 603.43 Million | 359.45 Million | 728.39 Million | 598.42 Million | 472.57 Million | 21.84 Million |
| Other Investing Activities | 164.8 Million | 111.35 Million | 185.1 Million | -439.16 Million | 214.87 Million | -2.09 Million |
| Financing Cash Flow | 95.69 Million | 2.95 Million | 11.96 Million | 633.59 Million | 58.96 Million | 771.18 Million |
| Debt repayment | - | - | - | - | - | -116.84 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 2.49 Million | 2.46 Million | 3.61 Million | 2.84 Million | 1.78 Million | - |
| Common Stock Issuance | 91.11 Million | 2.95 Million | 11.96 Million | 621.93 Million | 58.96 Million | 654.34 Million |
| Other Financing Activities | 95.69 Million | 2.95 Million | 11.96 Million | 8.81 Million | 58.96 Million | 771.18 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -7.5 Million | 4.86 Million | -767 Thousand | 615 Thousand | -985 Thousand | 8.8 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -7.8 Million | -1.16 Million | -31.32 Million | 53.3 Million | -5.89 Million | 3.29 Million |
| Cash at beginning of period | 72.19 Million | 183.6 Million | 192.8 Million | 179.42 Million | 93.73 Million | - |
| Cash at end of period | 93.44 Million | 72.19 Million | 183.6 Million | 192.8 Million | 179.42 Million | 93.73 Million |
| Capital Expenditure | -1.51 Million | -5.19 Million | -21.44 Million | -65.95 Million | -50.79 Million | -3.23 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 21.25 Million | -111.41 Million | -9.19 Million | 13.37 Million | 85.69 Million | 93.73 Million |
| Free Cash Flow | -239.24 Million | -225.71 Million | -206.25 Million | -181.05 Million | -188.14 Million | -47.88 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -66.35 Million | -65 Million | -89.25 Million | -327.26 Million | -61.31 Million | -77.98 Million |
| Depreciation & Amortization | 3.64 Million | 3.55 Million | 3.47 Million | 14.19 Million | 3.57 Million | 3.64 Million |
| Deferred income taxes | - | - | 20.16 Million | 7.5 Million | 1.6 Million | 140 Thousand |
| Stock-based compensation | 13.55 Million | 11.92 Million | 15.23 Million | 65.95 Million | 15.35 Million | 16.59 Million |
| Change in working capital | -16.75 Million | -4.44 Million | -3.4 Million | -15.3 Million | -14.88 Million | -4.39 Million |
| Other non-cash items | 16.35 Million | 17.21 Million | 75 Thousand | 17.18 Million | 147 Thousand | 150 Thousand |
| Investing Cash Flow | 74.61 Million | 22.13 Million | 67.46 Million | 163.28 Million | -34.26 Million | 17.16 Million |
| Investments in PPE | - | -8000.00 | -181 Thousand | -1.51 Million | -12 Thousand | -288 Thousand |
| Acquisitions | - | - | -67.64 Million | -164.8 Million | 34.25 Million | -17.44 Million |
| Investment purchases | -42.6 Million | -81.13 Million | -68.7 Million | -438.62 Million | -199.41 Million | -135.42 Million |
| Sales/Maturities of investments | 117.22 Million | 103.27 Million | 136.34 Million | 603.43 Million | 165.15 Million | 152.86 Million |
| Other Investing Activities | 74.61 Million | 22.14 Million | 67.64 Million | 164.8 Million | -34.25 Million | 17.44 Million |
| Financing Cash Flow | 108.6 Million | 1.65 Million | 155 Thousand | 95.69 Million | 4.28 Million | 89.52 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | 856 Thousand | 765 Thousand | 2.49 Million | - | - |
| Common Stock Issuance | 106.32 Million | 1.65 Million | -3.33 Million | 91.11 Million | 4.28 Million | 89.52 Million |
| Other Financing Activities | 2.28 Million | 1.65 Million | 155 Thousand | 95.69 Million | 4.28 Million | 89.52 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 6.8 Million | -118 Thousand | -302 Thousand | -7.5 Million | -3.96 Million | -4.29 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -23.55 Million | -4.32 Million | -3.09 Million | -7.8 Million | -10.92 Million | -105 Thousand |
| Cash at beginning of period | 51.03 Million | 93.44 Million | 79.53 Million | 72.19 Million | 165.05 Million | 120.22 Million |
| Cash at end of period | 170.66 Million | 51.03 Million | 93.44 Million | 93.44 Million | 79.53 Million | 165.05 Million |
| Capital Expenditure | - | -8000.00 | -181 Thousand | -1.51 Million | -12 Thousand | -288 Thousand |
| Effect of forex changes on cash | - | - | -72.63 Million | - | 100.86 Million | -28.23 Million |
| Net cash flow / Change in cash | 119.62 Million | -42.4 Million | 13.9 Million | 21.25 Million | -85.51 Million | 44.82 Million |
| Free Cash Flow | -63.58 Million | -55.9 Million | -53.88 Million | -239.24 Million | -55.54 Million | -62.14 Million |
6383
6884
5481
ELAN
A31
4071